Trilostane Treatment in a Dog with Pituitary-Dependent Hyperadrenocorticism |
Lim Young-Hwan
(College of Veterinary Medicine, Chungnam National University)
Lee Jung-Youn (Obihiro University of Agriculture and Veterinary Medicine) Cho Sung-Nam (College of Veterinary Medicine, Chungnam National University) Park Seong-Jun (College of Veterinary Medicine, Chungnam National University) Choi Ho-Jung (College of Veterinary Medicine, Chungnam National University) Lee Young-Won (College of Veterinary Medicine, Chungnam National University) Song Kun-Ho (College of Veterinary Medicine, Chungnam National University) |
1 | Ie Roux PA, van der Spuy ZM. Labor induction abortion utilizing trilostane, a 3-hydroxysteroid dehydrogenase inhibitor. Contraception 2005; 71: 343-347 DOI ScienceOn |
2 | Song JW, Park HM. Mitotane therapy and management of naturally occurring pituitary dependent hyperadrenocorticism (PDH) in a dog. J Vet Sci 2003; 20: 233-236 |
3 | Jenkin G, Gemmell RT, Thorburn GD. Induction of transient functional luteolysis in cyclic sheep by a 3-hydroxysteroid dehydrogenase inhibitor. J Endocrinol 1984; 100: 61-66 DOI ScienceOn |
4 | Neiger R, Ramsey I, O'Connor J, Hurley KJ, Mooney CT. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2002; 150: 799-804 DOI ScienceOn |
5 | Nelson RW, Couto CG. Disorder of the adrenal gland. In: Small animal internal medicine, 3rd ed. Philadelphia: Mosby. 2003: 779-798 |
6 | Peterson ME, Kintzer PP. Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane. Vet Clin North Am Small Anim Pract 1997; 27: 255-272 DOI |
7 | Reusch CE. Hyperadrenocorticism. In Ettinger SJ, Feldman EC (eds): Textbook of veterinary internal medicine, 6th ed. St. Louis: Elsevier Saunders, 2005: 1592-1612 |
8 | Rijnberk A, Belshaw BE. An alternative protocol for the medical management of canine pituitary-dependent hyperadrenocorticism. Vet Rec 1988; 122: 486-488 DOI ScienceOn |
9 | Braddock JA. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticis. Aust Vet J 2003; 81: 600-607 DOI ScienceOn |
10 | Schechter RD, Stabenfeldt GH, Gribble DH, Ling GV. Treatment of Cushing's sundrome in the dog with an adrenocorticolytic agent (o,p'DDD). J Am Vet Med Assoc 1973; 162: 629-639 |
11 | Ruckstuhl NS, Nett CS, Reusch CE. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 2002: 63: 506-512 DOI ScienceOn |
12 | DeClue AE, Cohn LA, Kerl ME. Medical therapies for canine pituitary dependent hyperadrenocorticism. Vet Med 2004: 519-527 |
13 | Kintzer PP, Peterson ME. Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1991; 5: 182-190 DOI |
14 | Peterson ME, Altszuler N, Nichols CE. Decreased insulin sensitivity and glucose tolerance in spontaneous canine hyperadrenocorticism. Res Vet Sci 1984; 36: 177-182 |
15 | Reusch CE, Steffen T, Hoerauf A. The efficacy of L-Deprenyl in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1999; 13: 291-301 DOI |
16 | 차봉수. Pathophysiology로 이해하는 내과학. 서울: 정담출판. 2002: 85-101 |
17 | Behrend EN, Kemppainen RJ, Clark TP, Salman MD, Peterson ME. Treatment of hyperadrenocorticism in dogs: a survey of internists and dermatologists. J Am Vet Med Assoc 1999; 215: 938-943 |